الفهرس 
Efficacy and safety profile of the adriamycin cyclophosphamide followed by docetaxel/cisplatin in locally advanced breast cancer
List of contentsOnly 14 pages are availabe for public view
 |  | from | 232 |  |  |
| | | from | 232 | | |
Abstract
Background: Neoadjuvant chemotherapy (NCT) using anthracycline - taxane based chemotherapy is the most effective and active regimen in patients with locally advanced breast cancer (LABC) by far. NCT produces pCR that predicts better outcome and increase the rate of Breast conservative surgery (BCS). Molecular subtyping and other markers e.g. ERCC1, Topo II Ü, Ki-67 are used as prognostic factors of response. This study aiming at evaluating the efficacy and safety profile of 4 cycles AC followed by 4 cycles of DC as NCT and detection of pCR with its subsequent effect on BCS, OS, DFS and its correlation with molecular subtypes and other markers e.g. ERCC1, Topo II Ü and Ki-67. Patients & Methods: One hundred and four female patients with LABC were recruited in a prospective phase II study at the Medical Oncology Department of the National Cancer Institute (NCI), Cairo University, during the period from March 2010 to July 2013 to receive eight cycles of NCT 4 cycles of (AC) followed by 4 cycles of (DC), responding patients were referred to surgery then to radiotherapy for local control. All patients were assessable for toxicity. ER, PR, Her2neu, Ki-67, ERCC1 and Topo II Ü were done to decide further management and correlate with the response to detect the prognosis. Results: One hundred and four female patients were evaluable for analysis of which median age: 51yrs, postmenopausal: 48.1%, median tumour size: 8 cm, stage IIB: 1%, stage IIIA: 14.4%, stage IIIB: 82.7%, stage IIIC: 1.9%, ER/PR positive: 78.8%, 25% were Her2neu positive. The cCR: (15.4%) after DC while pCR according to Miller was (20.2%), with tumour size mean:4.15± S.D 2.703, the correlation between DFS in positive and negative ERCC1 was statistically significant; (p-value {u2264} 0.01). Anaemia G2 & more was encountered in 27 patients (26%); regarding neutropenia G2 & more was 49 patients (47.1%). Peripheral neuritis was observed in 103 patients (99%) with G2 & more